China Resources Pharmaceutical Group Limited (China Resources Pharma, 03320) reported that its 60.26%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), recorded softer top- and bottom-line results for the nine months ended 30 September 2026, according to unaudited figures released on 27 October 2026.

Financial performance • Revenue reached RMB 8.07 billion, down 4.00% from RMB 8.40 billion in the prior-year period. • Net profit declined 6.51% year on year to RMB 1.31 billion, yielding a net margin of 16.21% (9M 2025: 16.65%).

Cash flow and liquidity • Net cash generated reached RMB 211.38 million, reversing a RMB 630.39 million outflow a year earlier. • Cash and cash equivalents stood at RMB 2.12 billion at period-end, 4.01% lower than the RMB 2.21 billion reported at 30 September 2025.

Balance sheet highlights (30 September 2026 vs. 31 December 2025) • Total assets expanded 10.00% to RMB 19.13 billion. • Total liabilities rose 24.62% to RMB 5.77 billion, lifting the liability-to-asset ratio to approximately 30.1%. • Owner’s equity increased 4.69% to RMB 13.36 billion.

Governance and reporting framework The disclosed numbers are prepared under PRC GAAP and have not been audited. They relate solely to CR Double-Crane and do not represent the consolidated position of China Resources Pharma. The parent company advises shareholders and potential investors to exercise caution when dealing in its securities and to refer to CR Double-Crane’s full quarterly report available on the Shanghai Stock Exchange website.